Please login to the form below

Not currently logged in
Email:
Password:

Clinigen

This page shows the latest Clinigen news and features for those working in and with pharma, biotech and healthcare.

Quantum Pharma confirms Clinigen takeover bid

Quantum Pharma confirms Clinigen takeover bid

Quantum Pharma confirms Clinigen takeover bid. Clinigen has until September 13 to make a formal offer. ... Shares in UK drugmaker Quantum Pharma are rising fast after it revealed with was in takeover talks with larger rival Clinigen Group.

Latest news

  • Clinigen acquires Idis for £225m Clinigen acquires Idis for £225m

    Clinigen acquires Idis for £225m. Acquisition makes them the global leader in unlicensed medicines. ... The ethical unlicensed supply market is estimated to be worth in excess of $5bn and upon completion, Clinigen claims it will become the market leader.

  • Eisai resubmits Fycompa to G-BA for pricing assessment Eisai resubmits Fycompa to G-BA for pricing assessment

    This prompted Eisai to suspend distribution of Fycompa in Germany, with the exception of an access programme managed by Clinigen for individual patients, until a favourable resolution can be reached.

  • Eisai lines-up Fycompa access programme for Germany Eisai lines-up Fycompa access programme for Germany

    data. Now Eisai has partnered with Clinigen Global Access Programs (GAP) on a named patient access programme that it said “ ensures continued supply of anti-epilepsy treatment at no cost to ... For this reason, Eisai has partnered with a specialist

  • BTG extends orphan drug distribution partnership with Clinigen

    BTG extends orphan drug distribution partnership with Clinigen. Deal covers treatment for overexposure to chemotherapy. ... Uridine triacetate is the third product that BTG has placed under Clinigen GAP's management and the latest programme will cover

  • Clinigen reshuffles management to prepare for growth

    Clinigen reshuffles management to prepare for growth. Changes will see Shaun Chilton move to chief operating officer. ... Clinigen has made a series of organisational changes that it says will help it achieve its five-year growth targets.

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 5 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Real world project management

    The Author. Debra Ainge is Head of Project Management at Clinigen GAP. ... 44 (0) 1283 495 010. Address:. Clinigen. Pitcairn House. Crown Square, First Avenue.

  • Clinigen

    Clinigen. Clinigen Global Access Programs specializes in the consultancy, development, management and implementation of access programs across the product lifecycle for biotechnology and pharmaceutical companies. ... Address:. Clinigen. Pitcairn House ,

  • Clinigen

    Clinigen. Clinigen Global Access Programs specializes in the consultancy, development, management and implementation of access programs across the product lifecycle for biotechnology and pharmaceutical companies. ... Address:. Clinigen. Pitcairn House ,

  • Market access

    Clinigen Global Access Programs specializes in the consultancy, development, management and implementation of access programs across the product lifecycle for biotechnology and pharmaceutical companies.

  • Regulatory affairs

    Clinigen Global Access Programs specializes in the consultancy, development, management and implementation of access programs across the product lifecycle for biotechnology and pharmaceutical companies.

More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics